問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of Nephrology

更新時間：2023-09-19

楊如燁
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊如燁

List

35Cases

2020-04-01 - 2023-12-31

Phase III

Completed
Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)

  • Condition/Disease

    Anaemia Associated With Chronic Kidney Disease

  • Test Drug

    Efepoetin alfa

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated6Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and High Blood Pressure

  • Test Drug

    tablet

Participate Sites
11Sites

Recruiting11Sites

2023-11-10 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    capsule

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-12-01 - 2030-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and High Blood Pressure

  • Test Drug

    tablet

Participate Sites
8Sites

Recruiting8Sites

2021-02-25 - 2024-06-05

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-08-31 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Not yet recruiting9Sites

Recruiting9Sites

2024-10-03 - 2029-10-04

Phase II/III

Not yet recruiting
A Phase 2b / 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis

  • Condition/Disease

    Kidney Disease

  • Test Drug

    injection

Participate Sites
7Sites

Recruiting7Sites

2021-08-01 - 2024-05-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-06-30 - 2030-12-31

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites

2025-04-01 - 2029-09-30

Phase III

Active
A phase 3, randomized, double-blind, placebo-controlled trial (PREVAIL) of felzartamab in adult patients with IgA nephropathy (IgAN).

  • Condition/Disease

    Immunoglobulin A nephropathy (IgA nephropathy, IgAN)

  • Test Drug

    Felzartamab

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB